These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 26856846)

  • 41. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
    Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
    J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.
    Zaidi ST; Al Omran S; Al Aithan AS; Al Sultan M
    J Clin Pharm Ther; 2014 Jun; 39(3):272-6. PubMed ID: 24593154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.
    Falagas ME; Rafailidis PI; Ioannidou E; Alexiou VG; Matthaiou DK; Karageorgopoulos DE; Kapaskelis A; Nikita D; Michalopoulos A
    Int J Antimicrob Agents; 2010 Feb; 35(2):194-9. PubMed ID: 20006471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Colistin nephrotoxicity in the ICU: Is it different in the geriatric patients?
    Aydoğan BB; Yıldırım F; Zerman A; Gönderen K; Türkoğlu M; Aygencel G
    Aging Clin Exp Res; 2018 Jun; 30(6):573-580. PubMed ID: 28866836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Colistin nephrotoxicity increases with age.
    Balkan II; Dogan M; Durdu B; Batirel A; Hakyemez IN; Cetin B; Karabay O; Gonen I; Ozkan AS; Uzun S; Demirkol ME; Akbas S; Kacmaz AB; Aras S; Mert A; Tabak F
    Scand J Infect Dis; 2014 Oct; 46(10):678-85. PubMed ID: 25073536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate.
    Horcajada JP; Sorlí L; Luque S; Benito N; Segura C; Campillo N; Montero M; Esteve E; Mirelis B; Pomar V; Cuquet J; Martí C; Garro P; Grau S
    Int J Antimicrob Agents; 2016 Dec; 48(6):725-727. PubMed ID: 28128096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between colistin dose and development of nephrotoxicity.
    Lee YJ; Wi YM; Kwon YJ; Kim SR; Chang SH; Cho S
    Crit Care Med; 2015 Jun; 43(6):1187-93. PubMed ID: 25756417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients.
    Wacharachaisurapol N; Phasomsap C; Sukkummee W; Phaisal W; Chanakul A; Wittayalertpanya S; Chariyavilaskul P; Puthanakit T
    Int J Antimicrob Agents; 2020 Jun; 55(6):105940. PubMed ID: 32179149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcome analysis of colistin-treated burn center patients.
    Wilkinson RE; Hill DM; Hickerson WL
    Burns; 2017 Sep; 43(6):1244-1249. PubMed ID: 28410932
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Colistimethate sodium and acute kidney injury: Incidence, risk factors, outcome and prognosis of renal function.
    Pampa-Saico S; Pintado V; Muriel A; Caravaca-Fontan F; Yerovi-León E; Rojo-Sanchis A; Del Rey JM; Teresa Tenorio M; Liaño F
    Nefrologia (Engl Ed); 2020; 40(6):647-654. PubMed ID: 32473742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.
    Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC
    Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Shedding light on the use of colistin: still gaps to be filled].
    Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia.
    Korkmaz Ekren P; Töreyin ZN; Berk Takır H; Kalamanoğlu Balcı M; Gaygısız Ü; Gürsel G; Ergan B; Yalçın A; Saltürk C; Aydoğdu M; Ergün R; Güven P; Ulubay G; Gürün Kaya A; Çeltik A; Uluer H; Bacakoğlu F; Sayıner A
    Tuberk Toraks; 2017 Dec; 65(4):271-281. PubMed ID: 29631525
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study.
    Rocco M; Montini L; Alessandri E; Venditti M; Laderchi A; De Pascale G; Raponi G; Vitale M; Pietropaoli P; Antonelli M
    Crit Care; 2013 Aug; 17(4):R174. PubMed ID: 23945197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients with septic shock caused by Gram-negative bacillus infection.
    Saito N; Sugiyama K; Ohnuma T; Kanemura T; Nasu M; Yoshidomi Y; Tsujimoto Y; Adachi H; Koami H; Tochiki A; Hori K; Wagatsuma Y; Matsumoto H
    PLoS One; 2017; 12(3):e0173633. PubMed ID: 28358803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Parenteral colistin for the treatment of severe infections: a single center experience.
    Tanita MT; Carrilho CM; Garcia JP; Festti J; Cardoso LT; Grion CM
    Rev Bras Ter Intensiva; 2013; 25(4):297-305. PubMed ID: 24553511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria.
    Ouderkirk JP; Nord JA; Turett GS; Kislak JW
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2659-62. PubMed ID: 12878536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Truong CB; Durham SH; Qian J
    Expert Opin Drug Saf; 2021 May; 20(5):603-609. PubMed ID: 33573405
    [No Abstract]   [Full Text] [Related]  

  • 60. Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?
    Sorli L; Luque S; Li J; Rodríguez E; Campillo N; Fernandez X; Soldado J; Domingo I; Montero M; Grau S; Horcajada JP
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30717123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.